{"resourceType": "Composition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report"], "versionId": "22", "lastUpdated": "2025-07-07T17:00:28.873Z"}, "title": "Comparative Evidence Report for QUARTET USA Trial", "type": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparativeEvidenceReport", "display": "ComparativeEvidenceReport"}], "text": "Comparative Evidence Report"}, "status": "final", "url": "https://fevir.net/resources/Composition/372776", "date": "2025-07-07T17:00:28.873Z", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "id": "372776", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/372776", "assigner": {"display": "Computable Publishing LLC"}}], "author": [{"display": "Joanne Dehnbostel"}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Comparative Evidence Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 372776. Revised 2025-07-07. Available at: https://fevir.net/resources/Composition/372776. Computable resource at: https://fevir.net/FLI/DocumentForComposition372776."}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "This is an example of a Comparative Evidence Report describing the QUARTET USA Randomized Controlled Trial for the EBM on FHIR Implementation Guide."}], "section": [{"title": "Introduction Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "introduction", "display": "Introduction"}]}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with hypertension. </span></p></div>"}}, {"title": "Population", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "population", "display": "Population"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "section": [{"title": "Screened Group", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "screened-group", "display": "Screened Group"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Ernolled Group", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "enrolled-group", "display": "Enrolled Group"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}, "entry": [{"reference": "Group/372797", "type": "Group", "display": "Enrolled Group for QUARTET USA Trial"}]}, {"title": "Analyzed Group", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "analyzed-group", "display": "Analyzed Group"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Population Definition", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "population-description", "display": "Population Description"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}, "entry": [{"reference": "Group/372778", "type": "Group", "display": "Eligibility Criteria for QUARTET USA Trial"}]}]}, {"title": "Intervention", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "intervention", "display": "Intervention"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "section": [{"title": "Intervention Description", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "intervention-description", "display": "Intervention Description"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}, "entry": [{"reference": "ActivityDefinition/375159", "type": "ActivityDefinition", "display": "Quadpill once daily"}]}, {"title": "Intervention Group", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "intervention-group", "display": "Intervention Group"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "Group/375175", "type": "Group", "display": "QUARTET USA Trial Quadpill group"}]}]}, {"title": "Comparator", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "comparator", "display": "Comparator"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "section": [{"title": "Comparator Description", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "comparator-description", "display": "Comparator Description"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "ActivityDefinition/375181", "type": "ActivityDefinition", "display": "Candesartan 8 mg once daily"}]}, {"title": "Comparator Group", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "comparator-group", "display": "Comparator Group"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "Group/375182", "type": "Group", "display": "QUARTET USA Trial Control Group"}]}, {"title": "Group Assignment (EvidenceVariable)", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "GroupAssignment", "display": "GroupAssignment"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "EvidenceVariable/375183", "type": "EvidenceVariable", "display": "GroupAssignment: Quadpill vs. Candesartan"}]}]}, {"title": "Research Study", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "research-study", "display": "Research Study"}]}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">Trial registration number: </span><a href=\"http://clinicaltrials.gov/show/NCT03640312\" title=\"See in ClinicalTrials.gov\" style=\"box-sizing: inherit; background-color: rgb(255, 255, 255); color: rgb(0, 113, 188); text-decoration: none; font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal;\">NCT03640312</a><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">.</span></p></div>"}, "entry": [{"reference": "ResearchStudy/367879", "type": "ResearchStudy", "display": "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension"}]}, {"title": "Methods Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "methods", "display": "Methods"}]}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">QUARTET USA was a randomized (1:1), double-blinded trial conducted in federally qualified health centers among adults with hypertension. Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks. If BP was &gt;130/&gt;80 mm Hg at 6 weeks in either arm, then participants received open label add-on amlodipine 5 mg. </span></p><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">The primary outcome was mean change in systolic blood pressure (SBP) at 12 weeks, controlling for baseline BP. Secondary outcomes included mean change in diastolic blood pressure (DBP), and safety included serious adverse events, relevant adverse drug effects, and electrolyte abnormalities. </span></p></div>"}}, {"title": "Baseline Measures", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "baseline-measures", "display": "Baseline Measures"}]}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">Among 62 participants randomized between August 2019-May 2022 (n = 32 intervention, n = 30 control), mean (SD) age was 52 (11.5) years, 45% were female, 73% identified as Hispanic, and 18% identified as Black. Baseline mean (SD) SBP was 138.1 (11.2) mmHg, and baseline mean (SD) DBP was 84.3 (10.5) mmHg. </span></p></div>"}, "entry": [{"reference": "Composition/370510", "type": "Composition", "display": "Baseline Characteristics Report for QUARTET Trial"}]}, {"title": "Participant Flow", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "participant-flow", "display": "Participant Flow"}], "text": "Participant Flow"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "Composition/370512", "type": "Composition", "display": "Participant Flow Report for QUARTET USA Trial"}]}, {"title": "Outcomes", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "outcome-measures", "display": "Outcome Measures"}], "text": "Outcomes"}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, &quot;Segoe UI&quot;, Roboto, Oxygen, Ubuntu, Cantarell, &quot;Fira Sans&quot;, &quot;Droid Sans&quot;, &quot;Helvetica Neue&quot;, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;\">In a modified intention-to-treat analysis, there was no significant difference in SBP (-4.8 mm Hg [95% CI: -10.8, 1.3, p = 0.123] and a -4.9 mmHg (95% CI: -8.6, -1.3, p = 0.009) greater mean DBP change in the intervention arm compared with the control arm at 12 weeks. Adverse events did not differ significantly between arms. The quadpill had a similar SBP and greater DBP lowering effect compared with candesartan 8 mg. </span></p></div>"}, "entry": [{"reference": "Composition/375280", "type": "Composition", "display": "Outcome Measure Report for QUARTET USA Trial"}, {"reference": "List/375184", "type": "List", "display": "Outcome Measure List for QUARTET USA Trial"}]}, {"title": "Summary of Findings", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "summary-of-findings", "display": "Summary of Findings"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Discussion Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "discussion", "display": "Discussion"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "References Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "references", "display": "References"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "Citation/367878", "type": "Citation", "display": "Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. (367878)"}]}, {"title": "Competing Interests Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "competing-interests", "display": "Competing Interests"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Acknowledgements Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "acknowledgements", "display": "Acknowledgements"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}, {"title": "Appendices Section", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "appendices", "display": "Appendices"}]}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "emptyReason": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/list-empty-reason", "code": "notstarted", "display": "Not Started"}]}}]}